Cite
HARVARD Citation
Drake, C. et al. (n.d.). Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer. p. . [Online].